Exopharm Limited develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia. The company's technology includes LOAD technology platform that enables loading of active pharmaceutical ingredient (API) into exosomes; Ligand-based Exosome Affinity Purification (LEAP) technology that solves the critical bottleneck of exosome isolation and purification; MASTER CELL BANK to manufacture clinical-grade engineered exosomes; EVPS technology platform that allows specific molecules to be attached to the surface of exosomes to target them to selected tissues, organs, or cell types; EXORIA, a novel and proprietary dye that tags invisible exosomes to enhance tracking in experimental studies and laboratory analysis; and FORMULATION H to enable the stable storage and transport of exosome medicines. Exopharm Limited has research collaboration agreements with Astellas Institute for Regenerative Medicine. The company was incorporated in 2013 and is based in Camberwell, Australia.
| Market Capitalization | $3.9548 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.017 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.04 |
| EBITDA | -5,056.978 |
| Profit Margin | -2.0903 |
| Operating Margin TTM | -1.9932 |
| Return on Assets TTM | -0.436 |
| Return on Equity TTM | -1.1025 |
| Revenue TTM | 3,411.087 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2015-06-30 | 0 | 0 | 0 | 0.236 |
| 2016-06-30 | 0 | 0 | 0 | 0.246 |
| 2017-06-30 | 0 | 0 | 0 | 0.565 |
| 2018-06-30 | 43.99 | 79.164 | -35.245 | 218.586 |
| 2019-06-30 | 28.79 | 496.688 | -496.688 | 2,371.671 |
| 2020-06-30 | 2,615.473 | 2,615.473 | 8,004.856 | |
| 2021-06-30 | 4,198.49 | 12,666.849 | ||
| 2022-06-30 | 99.73 | 99.73 | 14,212.257 | |
| 2023-06-30 | 618.568 | 618.568 | 10,210.126 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2015-06-30 | 0.05 | 1 | ||||
| 2016-06-30 | 0.196 | 1 | ||||
| 2017-06-30 | 0 | 0.76 | 0.76 | 1 | ||
| 2018-06-30 | 6,648.401 | 7,194.259 | 70.4 | 0 | 7,640.09 | |
| 2019-06-30 | 4,418.955 | 5,400.585 | 281.002 | 0 | 7,578.815 | |
| 2020-06-30 | 1,742.92 | 6,542.443 | 1,525.125 | 309.132 | 12,755.619 | |
| 2021-06-30 | 12,723.581 | 21,456.402 | 2,589.846 | 571.184 | 34,295.791 | |
| 2022-06-30 | 4,846.54 | 13,613.709 | 4,805.951 | 3,440.97 | 34,313.482 | |
| 2023-06-30 | 1,642.719 | 5,881.091 | 1,754.148 | 1,533.419 | 36,725.231 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2015-06-30 | -0.236 | -0.24 | 52.401 | |||
| 2016-06-30 | -0.246 | -0.25 | 52.401 | |||
| 2017-06-30 | -0.565 | -0.565 | 52.401 | |||
| 2018-06-30 | -174.597 | -93.932 | 52.401 | 52.401 | ||
| 2019-06-30 | -2,194.077 | -2,184.519 | 4,366.554 | 52.401 | 4,418.955 | |
| 2020-06-30 | -2,552.75 | -6,696.656 | -2,676.035 | 4,418.955 | 1,742.92 | |
| 2021-06-30 | -4,269.243 | -7,828.631 | 10,980.661 | 1,742.92 | 12,723.581 | |
| 2022-06-30 | -10,165.236 | -8,436.808 | -7,877.041 | 12,723.581 | 4,846.54 | |
| 2023-06-30 | -7,130.264 | -3,845.816 | -3,203.821 | 4,846.54 | 1,642.719 |